{"count": 10, "results": [{"_id": "32183017", "pmid": 32183017, "pmcid": "PMC7139992", "title": "Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells", "journal": "Cancers (Basel)", "authors": ["Mascaraque M", "Delgado-Wicke P", "Nuevo-Tapioles C", "Gracia-Cazaña T", "Abarca-Lachen E", "González S", "Cuezva JM", "Gilaberte Y", "Juarranz Á"], "date": "2020-03-13T00:00:00Z", "doi": "10.3390/cancers12030668", "meta_date_publication": "2020 Mar 13", "meta_volume": "12", "meta_issue": "3", "meta_pages": "", "score": 50281.74, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as an Adjuvant to Photodynamic Therapy in Resistant @<m>DISEASE_Carcinoma_Basal_Cell</m> @DISEASE_MESH:D002280 @@@Basal Cell Carcinoma@@@ Cells", "citations": {"NLM": "Mascaraque M, Delgado-Wicke P, Nuevo-Tapioles C, Gracia-Cazaña T, Abarca-Lachen E, González S, Cuezva JM, Gilaberte Y, Juarranz Á. Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells Cancers (Basel). 2020 Mar 13;12(3):. PMID: 32183017", "BibTeX": "@article{32183017, title={Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells}, author={Mascaraque M and Delgado-Wicke P and Nuevo-Tapioles C and Gracia-Cazaña T and Abarca-Lachen E and González S and Cuezva JM and Gilaberte Y and Juarranz Á}, journal={Cancers (Basel)}, volume={12}, number={3}}"}}, {"_id": "33610593", "pmid": 33610593, "title": "Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland.", "journal": "J Am Acad Dermatol", "authors": ["Adalsteinsson JA", "Muzumdar S", "Waldman R", "Wu R", "Ratner D", "Feng H", "Ungar J", "Silverberg JI", "Olafsdottir GH", "Kristjansson AK", "Tryggvadottir L", "Jonasson JG"], "date": "2021-07-01T00:00:00Z", "doi": "10.1016/j.jaad.2021.02.042", "meta_date_publication": "2021 Jul", "meta_volume": "85", "meta_issue": "1", "meta_pages": "56-61", "score": 50263.63, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is associated with decreased risk of @<m>DISEASE_Carcinoma_Basal_Cell</m> @DISEASE_MESH:D002280 @@@basal cell carcinoma@@@: A whole-population case-control study from Iceland.", "citations": {"NLM": "Adalsteinsson JA, Muzumdar S, Waldman R, Wu R, Ratner D, Feng H, Ungar J, Silverberg JI, Olafsdottir GH, Kristjansson AK, Tryggvadottir L, Jonasson JG. Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland. J Am Acad Dermatol. 2021 Jul;85(1):56-61. PMID: 33610593", "BibTeX": "@article{33610593, title={Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland.}, author={Adalsteinsson JA and Muzumdar S and Waldman R and Wu R and Ratner D and Feng H and Ungar J and Silverberg JI and Olafsdottir GH and Kristjansson AK and Tryggvadottir L and Jonasson JG}, journal={J Am Acad Dermatol}, volume={85}, number={1}, pages={56-61}}"}}, {"_id": "39630677", "pmid": 39630677, "title": "Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study.", "journal": "J Drugs Dermatol", "authors": ["Haq Z", "Mirza FN", "Abdi P", "Diaz MJ", "Libby TJ"], "date": "2024-12-01T00:00:00Z", "doi": "10.36849/jdd.8249", "meta_date_publication": "2024 Dec 1", "meta_volume": "23", "meta_issue": "12", "meta_pages": "1089-1095", "score": 50259.957, "text_hl": "Subgroup analyses revealed that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ exposure was associated with a decreased risk of @<m>DISEASE_Carcinoma_Basal_Cell</m> @DISEASE_MESH:D002280 @@@BCC@@@ across all sex and ethnicity groups. ", "citations": {"NLM": "Haq Z, Mirza FN, Abdi P, Diaz MJ, Libby TJ. Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study. J Drugs Dermatol. 2024 Dec 1;23(12):1089-1095. PMID: 39630677", "BibTeX": "@article{39630677, title={Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study.}, author={Haq Z and Mirza FN and Abdi P and Diaz MJ and Libby TJ}, journal={J Drugs Dermatol}, volume={23}, number={12}, pages={1089-1095}}"}}, {"_id": "35954309", "pmid": 35954309, "pmcid": "PMC9368307", "title": "The Protective Action of Metformin against Pro-Inflammatory Cytokine-Induced Human Islet Cell Damage and the Mechanisms Involved", "journal": "Cells", "authors": ["Giusti L", "Tesi M", "Ciregia F", "Marselli L", "Zallocco L", "Suleiman M", "De Luca C", "Del Guerra S", "Zuccarini M", "Trerotola M", "Eizirik DL", "Cnop M", "Mazzoni MR", "Marchetti P", "Lucacchini A", "Ronci M"], "date": "2022-08-08T00:00:00Z", "doi": "10.3390/cells11152465", "meta_date_publication": "2022 Aug 8", "meta_volume": "11", "meta_issue": "15", "meta_pages": "", "score": 50258.695, "text_hl": "The Protective Action of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ against Pro-Inflammatory @GENE_TNFRSF8 @GENE_943 @@@Cytokine@@@-Induced @SPECIES_9606 @@@Human@@@ Islet @<m>DISEASE_Carcinoma_Basal_Cell</m> @DISEASE_MESH:D002280 @@@Cell Damage@@@ and the Mechanisms Involved", "citations": {"NLM": "Giusti L, Tesi M, Ciregia F, Marselli L, Zallocco L, Suleiman M, De Luca C, Del Guerra S, Zuccarini M, Trerotola M, Eizirik DL, Cnop M, Mazzoni MR, Marchetti P, Lucacchini A, Ronci M. The Protective Action of Metformin against Pro-Inflammatory Cytokine-Induced Human Islet Cell Damage and the Mechanisms Involved Cells. 2022 Aug 8;11(15):. PMID: 35954309", "BibTeX": "@article{35954309, title={The Protective Action of Metformin against Pro-Inflammatory Cytokine-Induced Human Islet Cell Damage and the Mechanisms Involved}, author={Giusti L and Tesi M and Ciregia F and Marselli L and Zallocco L and Suleiman M and De Luca C and Del Guerra S and Zuccarini M and Trerotola M and Eizirik DL and Cnop M and Mazzoni MR and Marchetti P and Lucacchini A and Ronci M}, journal={Cells}, volume={11}, number={15}}"}}, {"_id": "35533029", "pmid": 35533029, "title": "Antidiabetic Treatment in Patients at High Risk for a Subsequent Keratinocyte Carcinoma.", "journal": "J Drugs Dermatol", "authors": ["Misitzis A", "Stratigos A", "Mastorakos G", "Weinstock M"], "date": "2022-05-01T00:00:00Z", "doi": "10.36849/JDD.6087", "meta_date_publication": "2022 May 1", "meta_volume": "21", "meta_issue": "5", "meta_pages": "502-505", "score": 50252.535, "text_hl": "@DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@Type II diabetes@@@ has been linked to the development of @DISEASE_Epidermal_Nevus @DISEASE_MESH:C580062 @@@keratinocyte carcinoma@@@ (@DISEASE_Epidermal_Nevus @DISEASE_MESH:C580062 @@@KC@@@), consisting of @<m>DISEASE_Carcinoma_Basal_Cell</m> @DISEASE_MESH:D002280 @@@basal cell carcinoma@@@ (@<m>DISEASE_Carcinoma_Basal_Cell</m> @DISEASE_MESH:D002280 @@@BCC@@@) and @DISEASE_Carcinoma_Squamous_Cell @DISEASE_MESH:D002294 @@@squamous cell carcinoma@@@ (@DISEASE_Carcinoma_Squamous_Cell @DISEASE_MESH:D002294 @@@SCC@@@). ", "citations": {"NLM": "Misitzis A, Stratigos A, Mastorakos G, Weinstock M. Antidiabetic Treatment in Patients at High Risk for a Subsequent Keratinocyte Carcinoma. J Drugs Dermatol. 2022 May 1;21(5):502-505. PMID: 35533029", "BibTeX": "@article{35533029, title={Antidiabetic Treatment in Patients at High Risk for a Subsequent Keratinocyte Carcinoma.}, author={Misitzis A and Stratigos A and Mastorakos G and Weinstock M}, journal={J Drugs Dermatol}, volume={21}, number={5}, pages={502-505}}"}}, {"_id": "33047438", "pmid": 33047438, "title": "The association of metformin use with keratinocyte carcinoma development in high-risk patients.", "journal": "Dermatol Ther", "authors": ["Misitzis A", "Stratigos AJ", "Beatson M", "Mastorakos G", "Dellavalle RP", "Weinstock MA", "Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group"], "date": "2020-11-01T00:00:00Z", "doi": "10.1111/dth.14402", "meta_date_publication": "2020 Nov", "meta_volume": "33", "meta_issue": "6", "meta_pages": "e14402", "score": 50252.39, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@-users compared to non-users had a significantly lower risk for @DISEASE_Carcinoma_Squamous_Cell @DISEASE_MESH:D002294 @@@squamous cell carcinoma@@@ with an adjusted Hazard ratio (HR): 0.45, (CI: 0.24-0.84, P < .01) and @<m>DISEASE_Carcinoma_Basal_Cell</m> @DISEASE_MESH:D002280 @@@basal cell carcinoma@@@ (HR: 0.70, CI: 0.49-0.97, P < .03). ", "citations": {"NLM": "Misitzis A, Stratigos AJ, Beatson M, Mastorakos G, Dellavalle RP, Weinstock MA, Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group. The association of metformin use with keratinocyte carcinoma development in high-risk patients. Dermatol Ther. 2020 Nov;33(6):e14402. PMID: 33047438", "BibTeX": "@article{33047438, title={The association of metformin use with keratinocyte carcinoma development in high-risk patients.}, author={Misitzis A and Stratigos AJ and Beatson M and Mastorakos G and Dellavalle RP and Weinstock MA and Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group}, journal={Dermatol Ther}, volume={33}, number={6}, pages={e14402}}"}}, {"_id": "37354675", "pmid": 37354675, "title": "NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.", "journal": "Georgian Med News", "authors": ["Tchernev G", "Kordeva S"], "date": "2023-04-01T00:00:00Z", "meta_date_publication": "2023 Apr", "meta_volume": "", "meta_issue": "337", "meta_pages": "63-67", "score": 50218.152, "text_hl": "The newly introduced regulatory norms in practice concern the potential/permissive availability of @CHEMICAL_Nitrosamines @CHEMICAL_MESH:D009602 @@@nitrosamines@@@ in a serious number of drugs: drugs with radically different mechanisms of action such as: @CHEMICAL_Ranitidine @CHEMICAL_MESH:D011899 @@@ranitidine@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, ACE inhibitors, beta blockers, thiazide diuretics, sartans, @CHEMICAL_Rifampin @CHEMICAL_MESH:D012293 @@@rifampicin@@@, but also probably a number of others. ", "citations": {"NLM": "Tchernev G, Kordeva S. NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER. Georgian Med News. 2023 Apr;(337):63-67. PMID: 37354675", "BibTeX": "@article{37354675, title={NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.}, author={Tchernev G and Kordeva S}, journal={Georgian Med News}, number={337}, pages={63-67}}"}}, {"_id": "27781075", "pmid": 27781075, "pmcid": "PMC5066015", "title": "Metformin Prevents Renal Stone Formation through an Antioxidant Mechanism In Vitro and In Vivo", "journal": "Oxid Med Cell Longev", "authors": ["Yang X", "Ding H", "Qin Z", "Zhang C", "Qi S", "Zhang H", "Yang T", "He Z", "Yang K", "Du E", "Liu C", "Xu Y", "Zhang Z"], "date": "2016-01-01T00:00:00Z", "doi": "10.1155/2016/4156075", "meta_date_publication": "2016", "meta_volume": "2016", "meta_issue": "", "meta_pages": "4156075", "score": 50063.41, "text_hl": "The present study was designed to investigate the preventive effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @<m>DISEASE_Carcinoma_Basal_Cell</m> @DISEASE_MESH:D002280 @@@renal tubular cell injury@@@ induced by @CHEMICAL_Oxalates @CHEMICAL_MESH:D010070 @@@oxalate@@@ and @DISEASE_Neointima @DISEASE_MESH:D058426 @@@stone formation@@@ in a hyperoxaluric @SPECIES_10116 @@@rat@@@ model. ", "citations": {"NLM": "Yang X, Ding H, Qin Z, Zhang C, Qi S, Zhang H, Yang T, He Z, Yang K, Du E, Liu C, Xu Y, Zhang Z. Metformin Prevents Renal Stone Formation through an Antioxidant Mechanism In Vitro and In Vivo Oxid Med Cell Longev. 2016;2016():4156075. PMID: 27781075", "BibTeX": "@article{27781075, title={Metformin Prevents Renal Stone Formation through an Antioxidant Mechanism In Vitro and In Vivo}, author={Yang X and Ding H and Qin Z and Zhang C and Qi S and Zhang H and Yang T and He Z and Yang K and Du E and Liu C and Xu Y and Zhang Z}, journal={Oxid Med Cell Longev}, volume={2016}, pages={4156075}}"}}, {"_id": "22864903", "pmid": 22864903, "title": "Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.", "journal": "Horm Metab Res", "authors": ["Ishibashi Y", "Matsui T", "Takeuchi M", "Yamagishi S"], "date": "2012-11-01T00:00:00Z", "doi": "10.1055/s-0032-1321878", "meta_date_publication": "2012 Nov", "meta_volume": "44", "meta_issue": "12", "meta_pages": "891-5", "score": 50052.062, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ inhibits advanced glycation end products (AGEs)-induced @<m>DISEASE_Carcinoma_Basal_Cell</m> @DISEASE_MESH:D002280 @@@renal tubular cell injury@@@ by suppressing @CHEMICAL_Reactive_Oxygen_Species @CHEMICAL_MESH:D017382 @@@reactive oxygen species@@@ generation via reducing @GENE_AGER @GENE_177 @@@receptor for AGEs@@@ (@GENE_AGER @GENE_177 @@@RAGE@@@) expression.", "citations": {"NLM": "Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Horm Metab Res. 2012 Nov;44(12):891-5. PMID: 22864903", "BibTeX": "@article{22864903, title={Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.}, author={Ishibashi Y and Matsui T and Takeuchi M and Yamagishi S}, journal={Horm Metab Res}, volume={44}, number={12}, pages={891-5}}"}}, {"_id": "21109968", "pmid": 21109968, "title": "The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.", "journal": "Oncol Rep", "authors": ["Vazquez-Martin A", "Oliveras-Ferraros C", "Cufí S", "Del Barco S", "Martin-Castillo B", "Lopez-Bonet E", "Menendez JA"], "date": "2011-01-01T00:00:00Z", "meta_date_publication": "2011 Jan", "meta_volume": "25", "meta_issue": "1", "meta_pages": "135-40", "score": 50038.883, "text_hl": "Here, we reveal that suppression of @GENE_CD24 @GENE_100133941 @@@CD24@@@ protein expression is a crucial event in the molecular mechanisms underlying the growth-inhibitory effects of the anti-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ drug @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @CELLLINE_CVCL:0419 @@@MDA-MB-468@@@ triple-negative (@<m>DISEASE_Carcinoma_Basal_Cell</m> @DISEASE_MESH:D002280 @@@basal-@@@like) @DISEASE_Breast_Neoplasms @DISEASE_MESH:D001943 @@@breast cancer@@@ cells. ", "citations": {"NLM": "Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Lopez-Bonet E, Menendez JA. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol Rep. 2011 Jan;25(1):135-40. PMID: 21109968", "BibTeX": "@article{21109968, title={The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.}, author={Vazquez-Martin A and Oliveras-Ferraros C and Cufí S and Del Barco S and Martin-Castillo B and Lopez-Bonet E and Menendez JA}, journal={Oncol Rep}, volume={25}, number={1}, pages={135-40}}"}}]}